ReP USP - Resultado da busca

Trabalho de evento-resumo periodico
Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide (2015)
Mattar, Andre; Ferreira, Luciana B.; Gebrim, Luiz H.; Hegg, Roberto; Maranhão, Raul Cavalcante
Fonte: Cancer Research. Nome do evento: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidades: FM, FCF
Assuntos: QUIMIOTERAPIA, NEOPLASIAS MAMÁRIAS (QUIMIOTERAPIA), ANTINEOPLÁSICOS, NANOCOMPOSITOS, CO-TERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATTAR, Andre et al. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06. Acesso em: 03 nov. 2025. , 2015
APA
Mattar, A., Ferreira, L. B., Gebrim, L. H., Hegg, R., & Maranhão, R. C. (2015). Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-P6-02-06
NLM
Mattar A, Ferreira LB, Gebrim LH, Hegg R, Maranhão RC. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide [Internet]. Cancer Research. 2015 ; 75[citado 2025 nov. 03 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06
Vancouver
Mattar A, Ferreira LB, Gebrim LH, Hegg R, Maranhão RC. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide [Internet]. Cancer Research. 2015 ; 75[citado 2025 nov. 03 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06
Trabalho de evento-resumo periodico
A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer (2015)
Mattar, Andre; Goncalves, Rodrigo; Ellis, Matthew J.; Hegg, Roberto
Fonte: Cancer Research. Nome do evento: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidade: FM
Assuntos: TERAPIA DA REPOSIÇÃO HORMONAL, NEOPLASIAS MAMÁRIAS (ETIOLOGIA;PREVENÇÃO E CONTROLE), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATTAR, Andre et al. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02. Acesso em: 03 nov. 2025. , 2015
APA
Mattar, A., Goncalves, R., Ellis, M. J., & Hegg, R. (2015). A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-OT2-1-02
NLM
Mattar A, Goncalves R, Ellis MJ, Hegg R. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2025 nov. 03 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02
Vancouver
Mattar A, Goncalves R, Ellis MJ, Hegg R. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2025 nov. 03 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02
Trabalho de evento-resumo periodico
Reduction of HER2-associated lipogenic phenotype by docosahexaenoic acid (DHA) induces apoptosis in breast tumor cells harboring HER2 overexpression (2015)
Ravacci, Graziela R.; Brentani, M. Mitzi; Festuccia, William Tadeu Lara ; Tortelli, Tharcisio; Waitzberg, Angela F.; Waitzberg, Dan L.
Fonte: Cancer Research. Nome do evento: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidades: FM, ICB
Assuntos: FENÓTIPOS, NEOPLASIAS MAMÁRIAS (GENÉTICA), APOPTROSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAVACCI, Graziela R. et al. Reduction of HER2-associated lipogenic phenotype by docosahexaenoic acid (DHA) induces apoptosis in breast tumor cells harboring HER2 overexpression. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-P1-08-08. Acesso em: 03 nov. 2025. , 2015
APA
Ravacci, G. R., Brentani, M. M., Festuccia, W. T. L., Tortelli, T., Waitzberg, A. F., & Waitzberg, D. L. (2015). Reduction of HER2-associated lipogenic phenotype by docosahexaenoic acid (DHA) induces apoptosis in breast tumor cells harboring HER2 overexpression. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-P1-08-08
NLM
Ravacci GR, Brentani MM, Festuccia WTL, Tortelli T, Waitzberg AF, Waitzberg DL. Reduction of HER2-associated lipogenic phenotype by docosahexaenoic acid (DHA) induces apoptosis in breast tumor cells harboring HER2 overexpression [Internet]. Cancer Research. 2015 ; 75[citado 2025 nov. 03 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P1-08-08
Vancouver
Ravacci GR, Brentani MM, Festuccia WTL, Tortelli T, Waitzberg AF, Waitzberg DL. Reduction of HER2-associated lipogenic phenotype by docosahexaenoic acid (DHA) induces apoptosis in breast tumor cells harboring HER2 overexpression [Internet]. Cancer Research. 2015 ; 75[citado 2025 nov. 03 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P1-08-08
Trabalho de evento-resumo periodico
Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2015)
Bell, Richard; Brown, Julia; Parmar, Mahesh; Toi, Mark; Suter, Thomas; Steger, Guenther; Pivot, Xavier; Mackey, John; Jackisch, Christian; Dent, Rebecca; Hall, Peter; Mecke, Almut; Morales, Leilani; Provencher, Louise; Staroslawska, Elzbieta; Hegg, Roberto; Vanlemmens, Laurence; Kirsch, Andreas; Schneeweiss, Andreas; Masuda, Norikazu; Overkamp, Friedrich; Cameron, David
Fonte: Cancer Research. Nome do evento: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidade: FM
Assuntos: QUIMIOTERAPIA, NEOPLASIAS MAMÁRIAS (TERAPIA), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BELL, Richard et al. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2. Acesso em: 03 nov. 2025. , 2015
APA
Bell, R., Brown, J., Parmar, M., Toi, M., Suter, T., Steger, G., et al. (2015). Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-PD2-2
NLM
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2025 nov. 03 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2
Vancouver
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2025 nov. 03 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2

Unidades USP

ReP

Filtros

Autores

Assuntos